RCT 225 outpatients in Iran showing lower mortality and hospitalization, and faster recovery with N-acetylcysteine and bromhexine. Baseline information per group is not provided, Figure 1 has the control group hospitalization status switched and the totals do not match, and the registration and previous version of this paper do not include the control group. N-acetylcysteine 600mg daily for 5 days, bromhexine 8mg tid for 5 days.
This study is excluded in meta
analysis:
inconsistent data, no baseline group details, control group not in previous version.
This study includes N-acetylcysteine and
bromhexine.
|
risk of death, 93.3% lower, RR 0.07, p = 0.01, treatment 0 of 75 (0.0%), control 7 of 75 (9.3%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of hospitalization, 78.0% lower, RR 0.22, p < 0.001, treatment 11 of 75 (14.7%), control 50 of 75 (66.7%), NNT 1.9.
|
|
recovery time, 15.9% lower, relative time 0.84, p = 0.02, treatment mean 12.65 (±0.9) n=75, control mean 15.04 (±8.557) n=75.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Ghayour et al., 3 Jan 2023, Randomized Controlled Trial, Iran, preprint, mean age 58.6, 4 authors, study period April 2022 - September 2022, trial
IRCT20220302054167N1.
Contact:
anahitaeslami1995@gmail.com.
